Pyrimidine Ring CDK2 Inhibitors for CDK4/6 Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK4/6 inhibitors face challenges with drug resistance due to amplification or overexpression of cyclin E, particularly in breast cancer, necessitating the development of novel, safe, and effective CDK2 inhibitors to overcome primary and secondary resistance.
Innovation Solution
Development of pyrimidine ring compounds and their pharmaceutically acceptable salts that selectively target CDK2, inhibiting its activity to potentially treat various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDK4/6 inhibitors are used to treat cancer, then tumor growth is inhibited initially, but drug resistance develops over time due to cyclin E amplification or overexpression
Solution Approach 1:
The patent uses a small molecule compound as an intermediary substance that bridges the gap between CDK4/6 inhibition and CDK2 inhibition. The compound selectively targets and inhibits CDK2 activity, providing a mediating mechanism to overcome resistance while the patient remains on CDK4/6 inhibitor therapy. This intermediary approach allows combination therapy to work synergistically.
Solution Approach 2:
The invention changes the kinetic parameter of the therapy by introducing a compound with different inhibition characteristics (IC50, selectivity profile) compared to CDK4/6 inhibitors. The small molecule compound exhibits preferential binding to CDK2 over CDK4/6, altering the therapeutic parameter landscape to address resistance mechanisms involving cyclin E overexpression.
2Reliability
If broad-spectrum CDK inhibitors (e.g., Dinaciclib, Seliciclib) are used to inhibit CDK2, then CDK2 activity is suppressed, but off-target effects occur due to inhibition of other CDK isoforms
Solution Approach 1:
The patent applies local quality by designing a compound with spatially differentiated binding affinity. The small molecule compound has high binding affinity specifically for CDK2's active site while exhibiting low affinity for CDK4, CDK6, and other CDK isoforms. This localized specificity at the molecular interaction level achieves selective inhibition without broad-spectrum effects.
Solution Approach 2:
The invention employs asymmetry in the compound's molecular structure to achieve asymmetric binding preferences. The chemical structure contains specific functional groups and spatial arrangements that create an asymmetric fit with CDK2's binding pocket, while not matching the binding pockets of other CDK isoforms, thereby achieving selective inhibition.
3Object-affected harmful factors
If novel CDK2 selective inhibitors are developed, then safety is improved by reducing off-target effects, but development complexity increases compared to using existing broad-spectrum inhibitors
Solution Approach 1:
The patent achieves universality by creating a compound that can function in multiple therapeutic contexts. The small molecule compound is designed to work as a standalone CDK2 inhibitor for CDK2-driven cancers and also serves as a complementary agent in combination with CDK4/6 inhibitors for resistant cases. This multi-functional design simplifies the overall therapeutic strategy despite the complexity of selective inhibition.
Data Source
AI summary
A pyrimidine ring compound represented by formula (III), or a pharmaceutically acceptable salt thereof, and an application thereof in preparation of a medication for treating related diseases.